If you have been reading about lyophilised powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
putative gene A specific nucleotide sequence suspected to be a functional gene based on the identification of its open reading frame. The gene is said to be "putative" in the sense that no function has yet been described for its products.
=== Integration of AMPK and ACC in the glucose-fatty acid cycle === Inhibition of fatty acid oxidation requires that ACC is active. Both AMPK and MCD are inactive and glucose uptake is stimulated. The LCFAs are then rerouted to esterification. These conditions exist in tissues rich in oxygen, in which AMPK is inactive and glucose inactivates the AMPK (researched in skeletal muscle). The inhibition of MCD suppresses the oxidation of fatty acids and stimulates glucose oxidation. In a study on MCD deficient mice there was no difference in the oxidation of fatty acids and glucose in the heart under aerobic conditions. It is theorized that the overexpression of fatty acids being used makes up for the lack of MCD.
The M242 is standard equipment on the U. S. Army M2 and M3 Bradley fighting vehicles; it is also in use on the LAV-25. Before the project was cancelled, the Mk44 Bushmaster II 30 mm chain gun (a successor to the M242) was used on the Marine Corps' Expeditionary Fighting Vehicle (EFV). The M242 is also a popular choice of primary armament for armored fighting vehicles manufactured around the world, such as Singapore's Bionix AFVs and as the Rafael Overhead Weapon Station-25 mounted on upgraded M113A2 Ultra IFVs.
Sources: en.wikipedia.org
== Substrates == The substrate specificity of 5-HEDH has been evaluated in a variety of intact cells and in crude microsome preparations isolated from cultured human blood monocytes differentiated into macrophages. These studies indicate that the enzyme efficiently oxidizes long chain unsaturated fatty acids possessing a hydroxy residue at carbon 5 and a trans double bond at carbon 6 to their corresponding 5-oxo products. It is therefore most efficient in metabolizing 5(S)-HETE to 5-oxo-ETE and, with somewhat lesser efficiency, in metabolizing other 5(S)-hydroxyl-6-trans unsaturated fatty acids such as 5(S)-hydroxy-eicosapentaenoic acid, 5(S)-hydroxy-eicosatrienoic acid, 5(S)-hydroxy-eicosadeinoic acid, 5(S)-hydroxy-eicosamonoenoic acid, 5(S)-hydroxy-octadecadienoic acid, 5(S),15(S)-dihydroxyeicosatetraenoic acid, and the 6-trans isomer of leukotriene B4 (which is a 5(S),12(S)-dihydroxyeicosatetraeonic acid) to their corresponding oxo analogs. 5-HEDH has relatively little ability to oxidize 5(S)-hydroxyl-tetradecadienoic acid, the R stereoisomer of 5(S)-HETE (5(R)-HETE), or a racemic mixture of 8-HETE, and does not oxidize 12(S)-HETE, 15(S)-HETE, leukotriene B4, a racemate mixture of 9-HETE, a racemate mixture of 11-HETE, or a 5(S)-hydroxy-6-trans 12 carbon dienoic fatty acid. 5-HEDH is therefore hydroxy dehydrogenase that acts in a stereospecific manner to oxidize 5(S)-hydoxy residues in 6-trans unsaturated intermediate but not short-chain fatty acids.
== External links == "Chart of Nuclides". National Nuclear Data Center (NNDC). Archived from the original on 2018-10-10. Retrieved 2014-08-21. Los Alamos National Laboratory's Chemistry Division: Periodic Table – Lawrencium Lawrencium at The Periodic Table of Videos (University of Nottingham)
Empagliflozin, sold under the brand name Jardiance ( JAR-dee-əns), among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes and/or for patients with established heart failure with reduced ejection fraction (HFrEF). Studies have shown great benefits for heart failure (HF) outcomes and decreased hospitalisations. It is taken by mouth. Common side effects of empagliflozin include genital yeast infections and hypotension, particularly in patients with volume depletion. Other symptoms such as nausea and vomiting may occur and seem more pronounced in combination with metformin. Rare but serious adverse events, such as euglycemic diabetic ketoacidosis (DKA) which may present with hyperventilation, lethargy, or mental status changes have been reported but are infrequent in trials. Other serious but rare serious adverse events include Fournier's gangrene, a severe skin infection of the groin, and diabetic ketoacidosis that may occur even with normal blood glucose levels. Use during pregnancy or breastfeeding is not recommended. Empagliflozin is a SGLT2 inhibitor: a reversible inhibitor of the sodium glucose co-transporter-2 (SGLT-2). It reduces the kidney's glucose reabsorption and excretes the excess glucose through the urine, thus its place in the treatment of type two diabetes. It is dependent on blood glucose concentrations and the glomerular filtration rate of the kidney.
Sources: en.wikipedia.org
This reacts up to 400 fold faster than the original pair with a rate constant of 5.5 ± 0.6 × 105 M−1 s−1. This version is back reactive with the two previous generations of SpyTag/SpyCatcher reagents. SpyTag/SpyCatcher react with specificity even when in the presence of bacterial and mammalian cell environments.
The neighbouring powers took advantage of the situation: the Habsburg Monarchy annexed the northwestern part of Moldavia, or Bukovina, in 1775, and the Russian Empire seized the eastern half of Moldavia, or Bessarabia, in 1812. A census revealed that the Romanians were more numerous than any other ethnic group in Transylvania in 1733, but legislation continued to use contemptuous adjectives (such as "tolerated" and "admitted") when referring to them. The Uniate bishop, Inocențiu Micu-Klein, who demanded recognition of the Romanians as the fourth privileged nation, was forced into exile. Uniate and Orthodox clerics and laymen jointly signed a plea for the Transylvanian Romanians' emancipation in 1791, but the monarch and the local authorities refused to grant their requests.
Nalorphine (INNTooltip International Nonproprietary Name; also known as N-allylnormorphine; brand names Lethidrone and Nalline) is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence. Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.